Acne vulgaris-Epidemiology Insights to 2023
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
Summary Orbis Research delivers key insights on the Acne vulgaris market in a new report titled “Acne vulgarisEpidemiology Insights to 2023“In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast 2023 Description “Acne Vulgaris (AV) Market - Epidemiology Insights-2023” Report provides an overview of the disease, historical and forecasted epidemiological data for the Diagnosed cases of Acne Vulgaris (AV) from 20132023 for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. Acne vulgaris is a common chronic skin disease/disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear. Get a PDF Sample of Report at: http://www.orbisresearch.com/contacts/request-sample/343494 . According to, based on the secondary sources and key opinion leaders (KOLs) the Diagnosed cases of Acne Vulgaris (AV) are increasing at the CAGR of XXXX% during the forecast period 2013-2023. The number of diagnosed Acne vulgaris cases in 7 major markets is expected to reach approximately 138 Million cases in 2023. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts. Scope
The report will help in developing business strategies by understanding the trends shaping and driving the Acne Vulgaris (AV) market. The Report covers the detailed historical and forecasted Acne Vulgaris (AV) epidemiology cases covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
To Browse the Entire Report, Visit : http://www.orbisresearch.com/reports/index/acne-vulgarisepidemiology-insights-to-2023 . The Key Players Mentioned in Report are: Report Introduction
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
Acne Vulgaris
Overview
Signs and symptoms
Types of Acne
Pathophysiology Diagnosis
Epidemiology and Patient Population
Total Number of cases- Geography wise- 2016 Total Number of cases- Geography wise- 2023 Total Number of cases- 7MM - 2016 Total Number of cases- 7MM - 2023
United States
Diagnosed Cases of Acne Vulgaris in United States
Germany
Diagnosed Cases of Acne Vulgaris in Germany
France
Diagnosed Cases of Acne Vulgaris in France
United Kingdom
Diagnosed Cases of Acne Vulgaris in United Kingdom
Spain
Diagnosed Cases of Acne Vulgaris in Spain
Italy
Diagnosed Cases of Acne Vulgaris in Italy
Japan
Diagnosed Cases of Acne Vulgaris in Japan
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019
Appendix Report Methodology Consulting Services Disclaimer About US Place a Purchase Order for this Report at: http://www.orbisresearch.com/contact/purchase/343494 . About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. Contact Information: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A. Phone No.: +1 (214) 884-6817; +9164101019 Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
www.orbisresearch.com; +1 (214) 884-6817; +9120-64101019